Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Trial Profile

AtRial Cardiopathy and Antithrombotic Drugs In Prevention After Cryptogenic Stroke

Status: Recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Apixaban (Primary) ; Aspirin
  • Indications Stroke
  • Focus Therapeutic Use
  • Acronyms ARCADIA
  • Most Recent Events

    • 08 Feb 2019 As of November 5, 2018, 434 subjects have been consented, of whom 113 have been randomized as per trial design presented at the International Stroke Conference 2019.
    • 08 Feb 2019 Trial design presented at the International Stroke Conference 2019
    • 17 Feb 2018 Planned primary completion date changed from 31 Oct 2021 to 18 Jan 2022.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top